Literature DB >> 1634910

Deterioration of dopaminergic pathways and alterations in cognition and motor functions.

B Dubois1, B Pillon, Y Agid.   

Abstract

Degeneration of central dopaminergic neurons is the most characteristic pathological feature of Parkinson's disease. It remains to be established to what extent these lesions explain the motor, cognitive and affective disorders observed in patients, but there are now some interesting clues to a possible solution.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1634910     DOI： 10.1007/bf00819560

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  34 in total

1.  Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease.

Authors:  S L Pullman; R L Watts; J L Juncos; T N Chase; J N Sanes
Journal:  Neurology       Date:  1988-02       Impact factor: 9.910

2.  Brain glutamic acid decarboxylase activity in Parkinson's disease.

Authors:  U K Rinne; H Laaksonen; P Riekkinen; V Sonninen
Journal:  Eur Neurol       Date:  1974       Impact factor: 1.710

3.  Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor.

Authors:  S Fahn; L R Libsch; R W Cutler
Journal:  J Neurol Sci       Date:  1971-12       Impact factor: 3.181

4.  Cognition and the basal ganglia. Separating mental and motor components of performance in Parkinson's disease.

Authors:  R D Rafal; M I Posner; J A Walker; F J Friedrich
Journal:  Brain       Date:  1984-12       Impact factor: 13.501

5.  Dopaminergic and cholinergic lesions in progressive supranuclear palsy.

Authors:  M Ruberg; F Javoy-Agid; E Hirsch; B Scatton; R LHeureux; J J Hauw; C Duyckaerts; F Gray; A Morel-Maroger; A Rascol
Journal:  Ann Neurol       Date:  1985-11       Impact factor: 10.422

6.  Fluctuations in plasma dopamine level impair memory in Parkinson's disease.

Authors:  S J Huber; H G Shulman; G W Paulson; E C Shuttleworth
Journal:  Neurology       Date:  1987-08       Impact factor: 9.910

7.  Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.

Authors:  G C Davis; A C Williams; S P Markey; M H Ebert; E D Caine; C M Reichert; I J Kopin
Journal:  Psychiatry Res       Date:  1979-12       Impact factor: 3.222

8.  Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test.

Authors:  B Pillon; B Dubois; A M Bonnet; M Esteguy; J Guimaraes; J M Vigouret; F Lhermitte; Y Agid
Journal:  Neurology       Date:  1989-06       Impact factor: 9.910

9.  Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations.

Authors:  F Boller; T Mizutani; U Roessmann; P Gambetti
Journal:  Ann Neurol       Date:  1980-04       Impact factor: 10.422

10.  Intellectual changes in patients with MPTP-induced parkinsonism.

Authors:  Y Stern; J W Langston
Journal:  Neurology       Date:  1985-10       Impact factor: 9.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.